Duality Biotherapeutics, Inc. Stock OTC Markets
Stocks
DYBT.Y
US2639081056
Pharmaceuticals
OTC Markets Traded| Market Cap | 16.23B 2.42B 2.12B 1.99B 1.82B 3.41B 232B 3.41B 23.87B 9.21B 118B 9.09B 8.9B 381B | P/E 2026 * |
-28.7x | P/E 2027 * | -29.1x |
|---|---|---|---|---|---|
| Enterprise Value | 16.85B 2.52B 2.2B 2.07B 1.89B 3.54B 240B 3.54B 24.79B 9.57B 123B 9.45B 9.24B 396B | EV / Sales 2026 * |
11.6x | EV / Sales 2027 * | 12x |
| Free-Float |
80.38% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Zhong Yuan Zhu
CEO | Chief Executive Officer | 56 | 03/07/2019 |
Shao Ren Zhang
DFI | Director of Finance/CFO | 40 | 23/03/2026 |
Mu Wen Hua
CTO | Chief Tech/Sci/R&D Officer | - | 07/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Zhong Yuan Zhu
CHM | Chairman | 56 | 03/07/2019 |
Hai Qing Hua
BRD | Director/Board Member | 45 | 23/03/2026 |
Shao Ren Zhang
BRD | Director/Board Member | 40 | 23/04/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 2.42B | |
| +0.72% | +3.85% | +34.96% | -2.54% | 80.27B | |
| +5.56% | +26.98% | +587.35% | +82.58% | 72.88B | |
| -0.82% | +2.77% | -10.35% | -29.15% | 61.51B | |
| -0.78% | -1.49% | -11.82% | +28.69% | 47.39B | |
| +0.23% | +3.83% | +4.70% | +168.51% | 46.58B | |
| +2.87% | +4.25% | +60.22% | -12.54% | 33.3B | |
| +1.83% | +4.26% | +49.81% | +118.47% | 25.73B | |
| +0.10% | +9.78% | +10.54% | +164.87% | 22.88B | |
| -0.25% | +1.96% | +60.92% | +102.71% | 15.82B | |
| Average | +0.45% | +6.00% | +87.37% | +69.07% | 45.15B | |
| Weighted average by Cap. | +0.40% | +7.38% | +120.89% | +52.31% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.46B 217M 190M 178M 163M 306M 20.77B 306M 2.14B 826M 10.6B 816M 798M 34.19B | 1.46B 219M 191M 179M 164M 307M 20.89B 307M 2.15B 831M 10.67B 821M 803M 34.39B |
| Net income | -601M -89.77M -78.45M -73.73M -67.29M -126M -8.58B -126M -885M -341M -4.38B -337M -330M -14.13B | -607M -90.66M -79.23M -74.46M -67.95M -128M -8.67B -128M -894M -345M -4.43B -340M -333M -14.27B |
| Net Debt | 627M 93.51M 81.72M 76.8M 70.09M 132M 8.94B 132M 922M 356M 4.57B 351M 343M 14.72B | 1.29B 192M 168M 158M 144M 270M 18.34B 270M 1.89B 730M 9.36B 720M 705M 30.19B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
